October 22, 2019
CheckMate -9LA, a Phase 3 Opdivo study met goals
Bristol-Myers Squibb study evaluated Opdivo plus low-dose Yervoy given concomitantly with two cycles of chemotherapy vs. chemotherapy alone for the…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Opdivo
September 30, 2019
Opdivo showed better in overall survival versus chemotherapy in advanced esophageal Cancer
Opdivo demonstrated a 23% reduction in the risk of death and 2.5-month improvement in median overall survival compared to chemotherapy, according to results from Phase 3 ATTRACTION-3 trial to be featured in a Presidential Symposium during the European Society for Medical Oncology 2019 Annual Congress.
September 28, 2019
Five-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma
Bristol-Myers squib’s Opdivo combined with Yervoy resulted in 52% of patients with being alive at five years, while 74% of patients treated with Opdivo plus Yervoy who were alive at five years remained treatment-free, the longest follow-up to date results for dual Immuno-Oncology (I-O) therapy in a Phase 3, randomized, controlled trial showed.
September 28, 2019
Opdivo superior recurrence-free survival (RFS) compared to Yervoy in resected high-risk melanoma patients
Bristol Myers Squib’s adjuvant treatment with Opdivo (nivolumab) further showed extended recurrence-free survival at three years in resected high-risk melanoma patients, being the longest follow-up of any PD-1 inhibitor in the adjuvant melanoma setting.
September 19, 2019
Bristol-Myers Squibb show breadth of oncology development program and focus on improving overall survival across multiple cancers
Overall survival data from CheckMate -227 Part 1 evaluating Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) in advanced non-small cell lung cancer featured in ESMO Presidential Symposium
September 10, 2019
Bristol-Myers Squibb: Long term survival with Opdivo in certain NSCLC tops traditional chemotherapy
Longest survival follow-up from a pooled analysis of randomized Phase 3 trials of an Immuno-Oncology therapy in this setting demonstrated…
July 26, 2019
Bristol-Myers Squibb study met its co-primary endpoint of overall survival with Opdivo plus low dose Yervoy
Study Met Its Co-Primary Endpoint of Overall Survival with Opdivo® (nivolumab) Plus Low Dose Yervoy® (ipilimumab) vs. Chemotherapy in First-Line Non-Small Cell Lung Cancer Patients Whose Tumors Express PD-L1 ≥1%
July 18, 2019
Three companies to evaluate the combination of Bayer’s kinase inhibitor Stivarga and BMS’s Opdivo
Bayer, Bristol-Myers Squibb Company (NYSE: BMY) and Ono Pharmaceutical Co., Ltd. (“Ono”) announced today the three companies have entered into a clinical collaboration agreement to evaluate the combination of Bayer’s kinase inhibitor Stivarga® (regorafenib) and Bristol-Myers Squibb’s / Ono’s anti-PD-1 immune checkpoint inhibitor, Opdivo® (nivolumab) in patients with micro-satellite stable metastatic colorectal cancer (MSS mCRC), the most common form of mCRC.1
July 10, 2019
Taris bio tests its TAR-200 with Opdivo
Taris Bio has dosed the first patient in a test of its investigational product TAR-200 combined with Bristol-Myers Squibb’s Opdivo.
June 24, 2019
Global Opdivo (Nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) Market Review & Forecast 2017-2026
DUBLIN–(BUSINESS WIRE)–The “Opdivo” drug pipelines has been added to ResearchAndMarkets.com’s offering. Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) is a fully human…